维普期刊资源整合服务平台（V6.5）

118篇 您的检索式：作者名="SARRAZIN C"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patient-derived oxidized low-density lipoprotein显示文摘	Westhaus S Bankwitz D Ernst S Rohrmann K Wappler I AgnéC Luchtefeld M Schieffer B Sarrazin C Manns M P Pietschmann T Ciesek S von Hahn T	2013	Hepatology2013，57，5：	1
2	Resistance to direct antiviral agents in patients with hepatitis C virus infection显示文摘	Sarrazin C Zeuzem S	2010	Gastroen terology2010，138，2：	1
3	SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders 显示文摘	Sarrazin C Rouzier R Wagner F	2007	Gastroenterology2007，132，4：	1
4	Assessment by transcription-mediated amplification,of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a 显示文摘	SARRAZIN C HENDRICKS DA SEDARATI F	2001	J Clin Microbiol2001，39，：	1
5	First insights into the structure and environmental setting of cold-seep communities in the Marmara Sea显示文摘	Ritt B Sarrazin J Caprais J C	2010	Deep-Sea Research Ⅰ:2010，57，9：	1
6	Comparison oS conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5 显示文摘	Sarrazin C Gartner B C Sizmann D	2006	J Clin Microbiol2006，44，3：	1
7	Viral determinants of resistance to treatment in patients with hepatitis C 显示文摘	Wohnsland A Hofmann WP Sarrazin C	2007	Clin Microbiol Rev2007，20，1：	1
8	Definition of rapid virologic response with a highly sensitive real- time PCR-based HCV RNA assay in peginterferon alfa- 2a plus ribavirin response-guided therapy显示文摘	Sarrazin C Shiffman ML Hadziyannis S J	2010	J Hepatol2010，52，6：	1
9	Mutations in the protein kinase -binding domain of the ns5a protein in patients infected with hepatitis C virus type la are associated with treatment response显示文摘	Sarrazin C Berg T Lee JH	2000	J Lnfect Dis2000，181，2：	1
10	Prediction of treatment outcome in pa- tients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therpy 显示文摘	Berg T Sarrazin C Herrmarm E	2003	Hepatology2003，37，5：	1
11	显示文摘	Biopo-Fonseca I Accar J Sarrazin C	1999	J Power Sources1999，79，：	1
12	Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir显示文摘	Sarrazin C Kieffer T L Bartels D Hanzelka B Müh U Welker M Wincheringer D Zhou Y Ch		0，，05：	1
13	Tenofovir for patients with lamivudine-resistant hepatitis B virus(HBV)infection and high HBV DNA level during adeforvir therpy显示文摘	Van Bommel F Zollner B Sarrazin C		0，，：	1
14	Antiviral strategies in hepatitis C virus infection显示文摘	Sarrazin C Hezode C Zeuzem S	2012	J Hepatol2012，，：	1
15	Polythiophene- based supercapacitors显示文摘	Laforgue A Simon P Sarrazin C	1999	J Power Source1999，80，：	1
16	Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy显示文摘	van Bommel F Zollner B Sarrazin C	2006	Hepatology2006，44，2：	1
17	Polypyrrole-Fe2O3 nanohybrid materials for electrochemical storage显示文摘	Mallouki M Tran-Van F Sarrazin C	2007	J Solid State Electrochem2007，11，3：	1
18	Telaprevir and pegylated interferon-alpha-2a inhibit wildtype and resistant genotype 1 hepatitis C virus replication in patients显示文摘	Kieffer TL Sarrazin C Miller JS	2007	Hepatology2007，46，3：	1
19	SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders显示文摘	Sarrazin C Rouzier R Wagner F	2007	Gastroenterology2007，132，4：	1
20	Review article : specifically targeted anti -viral therapy for hepatitis C - a new era in therapy显示文摘	Lange C M Sarrazin C Zeuzem S	2010	Aliment Pharmacol Ther2010，32，1：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示